**Guideline Page and Request** | **Panel Discussion** | **References** | **Vote**
---|---|---|---
Internal request; AML-7: Consider adding cytarabine + daunorubicin + cladribine as an induction regimen. | Based on the data in the noted reference, the panel consensus was to add the regimen of cytarabine + daunorubicin + cladribine as a category 1 option for induction therapy in patients younger than 60 years. | Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30:2441-2448. | 14 0 0